Adaptimmune Therapeutics plc (ADAP) financial statements (2020 and earlier)

Company profile

Business Address 60 JUBILEE AVENUE
ABINGDON, OXFORDSHIRE, OX14 4RX
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments103205208159
Cash and cash equivalents396884159
Short-term investments63137124 
Receivables3218121
Prepaid expense1066 
Other current assets000 
Other undisclosed current assets21438
Total current assets:147231230199
Noncurrent Assets
Operating lease, right-of-use asset21
Property, plant and equipment32364128
Intangible assets, net (including goodwill)2111
Intangible assets, net (excluding goodwill)2111
Restricted cash and investments4444
Other undisclosed noncurrent assets2453
Total noncurrent assets:61465136
TOTAL ASSETS:208277281235
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities32141916
Accounts payable64811
Accrued liabilities2724 
Employee-related liabilities 875
Deferred revenue3
Debt2   
Due to related parties  00
Deferred revenue and credits3911
Other liabilities 001
Other undisclosed current liabilities 101612
Total current liabilities:37247440
Noncurrent Liabilities
Long-term debt and lease obligation23   
Operating lease, liability23
Liabilities, other than long-term debt15425
Deferred revenue and credits 25
Other liabilities154 
Other undisclosed noncurrent liabilities   3
Total noncurrent liabilities:235428
Total liabilities:61307868
Stockholders' equity
Stockholders' equity attributable to parent148247203166
Common stock1111
Additional paid in capital583574455341
Accumulated other comprehensive loss(10)(10)(22)(14)
Accumulated deficit(426)(318)(232)(161)
Total stockholders' equity:148247203166
TOTAL LIABILITIES AND EQUITY:208277281235

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Revenue, net3814
Gross profit:2603814
Operating expenses(143)(142)(118)(87)
Operating loss:(142)(82)(81)(73)
Nonoperating income (expense)(2)(13)111
Investment income, nonoperating332 
Other nonoperating income (expense)(6)(16)91
Loss from continuing operations before equity method investments, income taxes:(144)(95)(70)(72)
Other undisclosed income from continuing operations before income taxes   1
Loss from continuing operations before income taxes:(144)(95)(70)(71)
Income tax expense(0)(0)(0)(1)
Net loss available to common stockholders, diluted:(144)(96)(70)(72)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Net loss:(144)(96)(70)(72)
Comprehensive loss:(144)(96)(70)(72)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent312(7)(6)
Comprehensive loss, net of tax, attributable to parent:(141)(84)(78)(78)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: